Email Updates

You are here

Efficacy Study Design

Friday, February 4, 2022

This graphic details the trial design behind HPTN 083 and HPTN 084, two-large scale efficacy trials testing cabotegravir, an antiretroviral formulated as an injectable for long-lasting pre- exposure prophylaxis (PrEP).

To learn more, read An Advocates' Primer on Long-Acting Injectable Cabotegravir for PrEP.